A pre-clinical study, focusing on human mammary gland carcinoma, showed that treatment with adoptive transfer of BrHPP + IL-2-expanded Vγ9Vδ2 T cells alone had a slight impact on tumor growth; however, when combined with trastuzumab (anti-Her2 Ab), the outcome was significantly improved [123]. Here, IL2 is linked to neoplasm.